{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T19:48:43Z","timestamp":1782848923563,"version":"3.54.5"},"reference-count":73,"publisher":"Oxford University Press (OUP)","issue":"2","funder":[{"name":"NIDA IRP Translational Analytical Core"},{"DOI":"10.13039\/501100007687","name":"Swedish Medical Society","doi-asserted-by":"publisher","award":["SLS-998225"],"award-info":[{"award-number":["SLS-998225"]}],"id":[{"id":"10.13039\/501100007687","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIH Center on Compulsive Behavior Fellowship","award":["UH2\/UH3-TR000963"],"award-info":[{"award-number":["UH2\/UH3-TR000963"]}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["1FI2GM154714-01"],"award-info":[{"award-number":["1FI2GM154714-01"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIAAA Division of Intramural Clinical and Biological Research"},{"DOI":"10.13039\/100030692","name":"NIDA Intramural Research Program","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100030692","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section","award":["ZIA-DA000635"],"award-info":[{"award-number":["ZIA-DA000635"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Ghrelin and liver-expressed antimicrobial peptide 2 (LEAP2) act via the growth hormone secretagogue receptor (GHSR), which modulates feeding, alcohol use, and endocrine and immune system function. The GHSR blocker PF-5190457 has potential as a novel pharmacotherapy for alcohol use disorder (AUD). This study aimed to characterize the effects of PF-5190457 on endocrine and immune markers in individuals with AUD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Pre-planned analyses used data from a randomized, double-blind, placebo-controlled, crossover human laboratory study in recently abstinent inpatients with AUD (N\u2009=\u200929; 8 females). Participants received PF-5190457 (100\u00a0mg twice daily) or matched placebo for 5+ days, separated by 2+ washout days. Blood was collected daily prior to dosing (T1). On days 4+, behavioral testing occurred post-dosing, followed by an additional blood collection ~2\u00a0hours post dosing (T2). Pharmacokinetic (PK: PF-5190457 and its active metabolite PF-6870961) and pharmacodynamic (PD: comprehensive panel of endocrine and immune markers) parameters were assessed over the course of dosing days. Additional exploratory analyses examined relationships between PK, PD, and behavioral measures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>PF-5190457 and PF-6870961 concentrations peaked at T2 and were elevated at T1 under drug vs placebo. LEAP2 levels were reduced under drug vs placebo but rebounded on the first washout day. PF-5190457 dramatically reduced growth hormone (GH) at T2, followed by an elevation of GH at T1 the following day. No other endocrine or immune markers differed significantly between drug and placebo. GH at T1 negatively correlated with the number of calories selected during a cafeteria-like virtual reality buffet experiment under drug, but not placebo conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>GHSR blockade with repeated dosing of PF-5190457 changed LEAP2 and GH concentrations but produced overall negligible effects on the endocrine and immune systems. These results further characterize the ghrelin system in AUD and its potential as a therapeutic target.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov Identifier: NCT02707055; registered November 3, 2016.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ijnp\/pyaf081","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T12:36:45Z","timestamp":1767098205000},"source":"Crossref","is-referenced-by-count":1,"title":["Pharmacokinetic and pharmacodynamic results from a randomized controlled study with the growth hormone secretagogue receptor blocker PF-5190457 in recently abstinent patients with alcohol use disorder"],"prefix":"10.1093","volume":"29","author":[{"given":"Ryan E","family":"Tyler","sequence":"first","affiliation":[{"name":"Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health , Baltimore, MD ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabea K","family":"Pfaff","sequence":"additional","affiliation":[{"name":"Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health , Baltimore, MD ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6875-1669","authenticated-orcid":false,"given":"Raja Muhammad Naseer","family":"Khan","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Laboratory, Clinical Center, National Institutes of Health , Bethesda, MD ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Loften","sequence":"additional","affiliation":[{"name":"Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health , Baltimore, MD ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Zurick","sequence":"additional","affiliation":[{"name":"Translational Analytical Core, National Institute on Drug Abuse Intramural Research Program , National Institutes of Health, Baltimore, MD ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zeng","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Laboratory, Clinical Center, National Institutes of Health , Bethesda, MD ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwatobi T","family":"Arisa","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Laboratory, Clinical Center, National Institutes of Health , Bethesda, MD ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Harvey","sequence":"additional","affiliation":[{"name":"Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health , Baltimore, MD ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Akhlaghi","sequence":"additional","affiliation":[{"name":"Ventyx Biosciences , San Diego, CA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D","family":"Figg","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Laboratory, Clinical Center, National Institutes of Health , Bethesda, MD ,","place":["United States"]},{"name":"Clinical Pharmacology Program, Center for Cancer Research, National Cancer Institute , National Institutes of Health, Bethesda, MD ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0902-4212","authenticated-orcid":false,"given":"Mehdi","family":"Farokhnia","sequence":"additional","affiliation":[{"name":"Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health , Baltimore, MD ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4495-037X","authenticated-orcid":false,"given":"Lorenzo","family":"Leggio","sequence":"additional","affiliation":[{"name":"Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health , Baltimore, MD ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,31]]},"reference":[{"key":"2026031009291654600_ref1","volume-title":"Alcohol Facts and Statistics","author":"NIAAA"},{"key":"2026031009291654600_ref2","doi-asserted-by":"publisher","first-page":"eaax4043","DOI":"10.1126\/sciadv.aax4043","article-title":"Advances in the science and treatment of alcohol use disorder","volume":"5","author":"Witkiewitz","year":"2019","journal-title":"Sci Adv"},{"key":"2026031009291654600_ref3","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/978-3-031-32483-3_16","volume-title":"Alcohol and Alcohol-Related Diseases","author":"L\u00e9k\u00f3","year":"2023"},{"key":"2026031009291654600_ref4","doi-asserted-by":"publisher","first-page":"4837","DOI":"10.3390\/ijms15034837","article-title":"The growth hormone secretagogue receptor: its intracellular signaling and regulation","volume":"15","author":"Yin","year":"2014","journal-title":"Int J Mol Sci"},{"key":"2026031009291654600_ref5","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/45230","article-title":"Ghrelin is a growth-hormone-releasing acylated peptide from stomach","volume":"402","author":"Kojima","year":"1999","journal-title":"Nature."},{"key":"2026031009291654600_ref6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.mce.2011.03.021","article-title":"The role of ghrelin in GH secretion and GH disorders","volume":"340","author":"Nass","year":"2011","journal-title":"Mol Cell Endocrinol"},{"key":"2026031009291654600_ref7","doi-asserted-by":"publisher","first-page":"e13224","DOI":"10.1111\/jne.13224","article-title":"Toward a consensus nomenclature for ghrelin, its non-acylated form, liver expressed antimicrobial peptide 2 and growth hormone secretagogue receptor","volume":"35","author":"Perell\u00f3","year":"2023","journal-title":"J Neuroendocrinol"},{"key":"2026031009291654600_ref8","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/35051587","article-title":"A role for ghrelin in the central regulation of feeding","volume":"409","author":"Nakazato","year":"2001","journal-title":"Nature."},{"key":"2026031009291654600_ref9","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/b978-0-12-381272-8.00010-6","article-title":"Enzymatic characterization of GOAT, ghrelin O-acyltransferase","volume":"514","author":"Ohgusu","year":"2012","journal-title":"Methods Enzymol"},{"key":"2026031009291654600_ref10","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.cmet.2017.10.016","article-title":"LEAP2 is an endogenous antagonist of the ghrelin receptor","volume":"27","author":"Ge","year":"2018","journal-title":"Cell Metab"},{"key":"2026031009291654600_ref11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.physbeh.2019.02.008","article-title":"Ghrelin: from a gut hormone to a potential therapeutic target for alcohol use disorder","volume":"204","author":"Farokhnia","year":"2019","journal-title":"Physiol Behav"},{"key":"2026031009291654600_ref12","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1111\/acer.14967","article-title":"Role of the ghrelin system in alcohol use disorder and alcohol-associated liver disease: a narrative review","volume":"46","author":"Kharbanda","year":"2022","journal-title":"Alcohol Clin Exp Res"},{"key":"2026031009291654600_ref13","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/bs.irn.2024.07.006","article-title":"Ghrelin system and GLP-1 as potential treatment targets for alcohol use disorder","volume":"178","author":"Jerlhag","year":"2024","journal-title":"Int Rev Neurobiol"},{"key":"2026031009291654600_ref14","doi-asserted-by":"publisher","first-page":"11318","DOI":"10.1073\/pnas.0812809106","article-title":"Requirement of central ghrelin signaling for alcohol reward","volume":"106","author":"Jerlhag","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026031009291654600_ref15","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/j.1369-1600.2010.00280.x","article-title":"Ghrelin receptor (GHS-R1A) antagonism suppresses both operant alcohol self-administration and high alcohol consumption in rats","volume":"17","author":"Landgren","year":"2012","journal-title":"Addict Biol"},{"key":"2026031009291654600_ref16","doi-asserted-by":"publisher","first-page":"e71284","DOI":"10.1371\/journal.pone.0071284","article-title":"Ghrelin receptor (GHS-R1A) antagonism suppresses both alcohol consumption and the alcohol deprivation effect in rats following long-term voluntary alcohol consumption","volume":"8","author":"Suchankova","year":"2013","journal-title":"PLoS One"},{"key":"2026031009291654600_ref17","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.peptides.2013.02.008","article-title":"Ghrelin knockout mice show decreased voluntary alcohol consumption and reduced ethanol-induced conditioned place preference","volume":"43","author":"Bahi","year":"2013","journal-title":"Peptides."},{"key":"2026031009291654600_ref18","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1111\/acer.12499","article-title":"The effects of ghrelin antagonists [D-Lys(3) ]-GHRP-6 or JMV2959 on ethanol, water, and food intake in C57BL\/6J mice","volume":"38","author":"Gomez","year":"2014","journal-title":"Alcohol Clin Exp Res"},{"key":"2026031009291654600_ref19","doi-asserted-by":"publisher","first-page":"e12663","DOI":"10.1111\/jne.12663","article-title":"Ghrelin receptor deletion reduces binge-like alcohol drinking in rats","volume":"31","author":"Zallar","year":"2019","journal-title":"J Neuroendocrinol"},{"key":"2026031009291654600_ref20","doi-asserted-by":"publisher","first-page":"109643","DOI":"10.1016\/j.neuropharm.2023.109643","article-title":"Pharmacological GHSR (ghrelin receptor) blockade reduces alcohol binge-like drinking in male and female mice","volume":"238","author":"Richardson","year":"2023","journal-title":"Neuropharmacology."},{"key":"2026031009291654600_ref21","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-024-02713-3","article-title":"GHSR blockade, but not reduction of peripherally circulating ghrelin via \u03b2(1)-adrenergic receptor antagonism, decreases binge-like alcohol drinking in mice","volume":"30","author":"Richardson","year":"2024","journal-title":"Mol Psychiatry"},{"key":"2026031009291654600_ref22","doi-asserted-by":"publisher","first-page":"111341","DOI":"10.1016\/j.pnpbp.2025.111341","article-title":"Evidence for independent actions of the CRF and ghrelin systems in binge-like alcohol drinking in mice","volume":"138","author":"Richardson","year":"2025","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"2026031009291654600_ref23","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/j.1369-1600.2006.00041.x","article-title":"Ghrelin administration into tegmental areas stimulates locomotor activity and increases extracellular concentration of dopamine in the nucleus accumbens","volume":"12","author":"Jerlhag","year":"2007","journal-title":"Addict Biol"},{"key":"2026031009291654600_ref24","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/j.1369-1600.2010.00308.x","article-title":"Ghrelin system in alcohol-dependent subjects: role of plasma ghrelin levels in alcohol drinking and craving","volume":"17","author":"Leggio","year":"2012","journal-title":"Addict Biol"},{"key":"2026031009291654600_ref25","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.biopsych.2014.03.019","article-title":"Intravenous ghrelin administration increases alcohol craving in alcohol-dependent heavy drinkers: a preliminary investigation","volume":"76","author":"Leggio","year":"2014","journal-title":"Biol Psychiatry"},{"key":"2026031009291654600_ref26","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1038\/mp.2017.226","article-title":"Exogenous ghrelin administration increases alcohol self-administration and modulates brain functional activity in heavy-drinking alcohol-dependent individuals","volume":"23","author":"Farokhnia","year":"2018","journal-title":"Mol Psychiatry"},{"key":"2026031009291654600_ref27","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1021\/ml400473x","article-title":"Discovery of PF-5190457, a potent, selective, and orally bioavailable ghrelin receptor inverse agonist clinical candidate","volume":"5","author":"Bhattacharya","year":"2014","journal-title":"ACS Med Chem Lett"},{"key":"2026031009291654600_ref28","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1111\/bph.13439","article-title":"Pharmacological characterization of the first in class clinical candidate PF-05190457: a selective ghrelin receptor competitive antagonist with inverse agonism that increases vagal afferent firing and glucose-dependent insulin secretion ex vivo","volume":"173","author":"Kong","year":"2016","journal-title":"Br J Pharmacol"},{"key":"2026031009291654600_ref29","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/bcp.13127","article-title":"Pharmacokinetics and pharmacodynamics of PF-05190457: the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects","volume":"83","author":"Denney","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"2026031009291654600_ref30","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41380-018-0064-y","article-title":"The novel ghrelin receptor inverse agonist PF-5190457 administered with alcohol: preclinical safety experiments and a phase 1b human laboratory study","volume":"25","author":"Lee","year":"2020","journal-title":"Mol Psychiatry"},{"key":"2026031009291654600_ref31","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.182331","article-title":"A randomized, double-blind, placebo-controlled study of a GHSR blocker in people with alcohol use disorder","volume":"9","author":"Faulkner","year":"2024","journal-title":"JCI Insight"},{"key":"2026031009291654600_ref32","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1124\/dmd.119.087015","article-title":"Role of molybdenum-containing enzymes in the biotransformation of the novel ghrelin receptor inverse agonist PF-5190457: a reverse translational bed-to-bench approach","volume":"47","author":"Adusumalli","year":"2019","journal-title":"Drug Metab Dispos"},{"key":"2026031009291654600_ref33","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1124\/jpet.122.001393","article-title":"Initial pharmacological characterization of a major hydroxy metabolite of PF-5190457: inverse agonist activity of PF-6870961 at the ghrelin receptor","volume":"386","author":"Deschaine","year":"2023","journal-title":"J Pharmacol Exp Ther"},{"key":"2026031009291654600_ref34","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.ecl.2013.05.008","article-title":"Effects of alcohol on the endocrine system","volume":"42","author":"Rachdaoui","year":"2013","journal-title":"Endocrinol Metab Clin N Am"},{"key":"2026031009291654600_ref35","doi-asserted-by":"crossref","first-page":"331","DOI":"10.35946\/arcr.v37.2.15","article-title":"Neuroimmune function and the consequences of alcohol exposure","volume":"37","author":"Crews","year":"2015","journal-title":"Alcohol Res."},{"key":"2026031009291654600_ref36","doi-asserted-by":"publisher","first-page":"e0177","DOI":"10.1097\/cld.0000000000000177","article-title":"Biological basis of addiction and alcohol use disorder","volume":"23","author":"Tyler","year":"2024","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"2026031009291654600_ref37","doi-asserted-by":"crossref","first-page":"255","DOI":"10.35946\/arcr.v38.2.08","article-title":"Pathophysiology of the effects of alcohol abuse on the endocrine system","volume":"38","author":"Rachdaoui","year":"2017","journal-title":"Alcohol Res."},{"key":"2026031009291654600_ref38","doi-asserted-by":"crossref","first-page":"185","DOI":"10.35946\/arcr.v37.2.04","article-title":"Impact of alcohol abuse on the adaptive immune system","volume":"37","author":"Pasala","year":"2015","journal-title":"Alcohol Res"},{"key":"2026031009291654600_ref39","doi-asserted-by":"publisher","first-page":"03","DOI":"10.35946\/arcr.v45.1.03","article-title":"Influence of alcohol on the intestinal immune system","volume":"45","author":"Kreimeyer","year":"2025","journal-title":"Alcohol Res"},{"key":"2026031009291654600_ref40","doi-asserted-by":"publisher","first-page":"e0302195","DOI":"10.1371\/journal.pone.0302195","article-title":"Gut microbial diversity and functional characterization in people with alcohol use disorder: a case-control study","volume":"19","author":"Piacentino","year":"2024","journal-title":"PLoS One"},{"key":"2026031009291654600_ref41","doi-asserted-by":"publisher","first-page":"e70039","DOI":"10.1111\/adb.70039","article-title":"Circulating immune and endocrine markers in currently drinking and abstinent individuals with alcohol use disorder and controls","volume":"30","author":"Tyler","year":"2025","journal-title":"Addict Biol"},{"key":"2026031009291654600_ref42","doi-asserted-by":"publisher","first-page":"178","DOI":"10.18632\/aging.100888","article-title":"Ghrelin receptor regulates adipose tissue inflammation in aging","volume":"8","author":"Lin","year":"2016","journal-title":"Aging (Albany NY)"},{"key":"2026031009291654600_ref43","doi-asserted-by":"publisher","first-page":"107711","DOI":"10.1016\/j.neuropharm.2019.107711","article-title":"Intravenous administration of ghrelin increases serum cortisol and aldosterone concentrations in heavy-drinking alcohol-dependent individuals: results from a double-blind, placebo-controlled human laboratory study","volume":"158","author":"Haass-Koffler","year":"2019","journal-title":"Neuropharmacology."},{"key":"2026031009291654600_ref44","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1093\/ijnp\/pyab004","article-title":"Neuroendocrine response to exogenous ghrelin administration, combined with alcohol, in heavy-drinking individuals: findings from a randomized, double-blind, placebo-controlled human laboratory study","volume":"24","author":"Farokhnia","year":"2021","journal-title":"Int J Neuropsychopharmacol"},{"key":"2026031009291654600_ref45","doi-asserted-by":"publisher","first-page":"e22508","DOI":"10.1096\/fj.202200634R","article-title":"Potential role of ghrelin in the regulation of inflammation","volume":"36","author":"Ma","year":"2022","journal-title":"FASEB J"},{"key":"2026031009291654600_ref46","doi-asserted-by":"publisher","first-page":"146851","DOI":"10.1016\/j.brainres.2020.146851","article-title":"Effects of exogenous ghrelin administration and ghrelin receptor blockade, in combination with alcohol, on peripheral inflammatory markers in heavy-drinking individuals: results from two human laboratory studies","volume":"1740","author":"Farokhnia","year":"2020","journal-title":"Brain Res"},{"key":"2026031009291654600_ref47","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/s0026-0495(71)80006-9","article-title":"Effects of alcohol ingestion on growth hormone levels: their relation to 11-hydroxycorticoid levels and serum FFA","volume":"20","author":"Bellet","year":"1971","journal-title":"Metabolism."},{"key":"2026031009291654600_ref48","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/j.1365-2265.1983.tb00587.x","article-title":"Increased plasma pancreatic polypeptide in chronic alcohol abuse","volume":"18","author":"Fink","year":"1983","journal-title":"Clin Endocrinol"},{"key":"2026031009291654600_ref49","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1189\/jlb.0602313","article-title":"Interleukin-18","volume":"73","author":"Gracie","year":"2003","journal-title":"J Leukoc Biol"},{"key":"2026031009291654600_ref50","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/j.1530-0277.2007.00589.x","article-title":"Insulin but not insulin growth factor-1 correlates with craving in currently drinking alcohol-dependent patients","volume":"32","author":"Leggio","year":"2008","journal-title":"Alcohol Clin Exp Res"},{"key":"2026031009291654600_ref51","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.neuropharm.2011.02.028","article-title":"Insulin signaling and addiction","volume":"61","author":"Daws","year":"2011","journal-title":"Neuropharmacology."},{"key":"2026031009291654600_ref52","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1530\/ec-19-0317","article-title":"Gluco-metabolic effects of oral and intravenous alcohol administration in men","volume":"8","author":"Lanng","year":"2019","journal-title":"Endocr Connect"},{"key":"2026031009291654600_ref53","doi-asserted-by":"publisher","first-page":"101967","DOI":"10.1016\/j.ajp.2020.101967","article-title":"Leptin levels in alcohol dependent patients and their relationship with withdrawal and craving","volume":"51","author":"Mehta","year":"2020","journal-title":"Asian J Psychiatr"},{"key":"2026031009291654600_ref54","doi-asserted-by":"publisher","first-page":"17554","DOI":"10.1038\/s41598-023-44798-w","article-title":"Effect of alcohol on brain-derived neurotrophic factor (BDNF) blood levels: a systematic review and meta-analysis","volume":"13","author":"Shafiee","year":"2023","journal-title":"Sci Rep"},{"key":"2026031009291654600_ref55","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/j.1365-2249.1994.tb06047.x","article-title":"IL-8 as an important chemoattractant for neutrophils in ulcerative colitis and Crohn's disease","volume":"96","author":"Mitsuyama","year":"2008","journal-title":"Clin Exp Immunol"},{"key":"2026031009291654600_ref56","doi-asserted-by":"publisher","first-page":"a016295","DOI":"10.1101\/cshperspect.a016295","article-title":"IL-6 in inflammation, immunity, and disease","volume":"6","author":"Tanaka","year":"2014","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2026031009291654600_ref57","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22052719","article-title":"The role of tumor necrosis factor alpha (TNF-\u03b1) in autoimmune disease and current TNF-\u03b1 inhibitors in therapeutics","volume":"22","author":"Jang","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026031009291654600_ref58","doi-asserted-by":"publisher","first-page":"e081123","DOI":"10.1136\/bmj-2024-081123","article-title":"CONSORT 2025 statement: updated guideline for reporting randomised trials","volume":"389","author":"Hopewell","year":"2025","journal-title":"BMJ."},{"key":"2026031009291654600_ref59","volume-title":"Structured Clinical Interview for DSM-5 Disorders\u2014Clinician Version (SCID-5-CV)","author":"American","year":"2016"},{"key":"2026031009291654600_ref60","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s40262-020-00942-7","article-title":"A population pharmacokinetic analysis of PF-5190457, a novel ghrelin receptor inverse agonist in healthy volunteers and in heavy alcohol drinkers","volume":"60","author":"Cobbina","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"2026031009291654600_ref61","doi-asserted-by":"publisher","first-page":"121820","DOI":"10.1016\/j.jchromb.2019.121820","article-title":"Development and validation of an assay for a novel ghrelin receptor inverse agonist PF-5190457 and its major hydroxy metabolite (PF-6870961) by LC-MS\/MS in human plasma","volume":"1130-1131","author":"Adusumalli","year":"2019","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"2026031009291654600_ref62","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.appet.2017.12.007","article-title":"Validity of assessing child feeding with virtual reality","volume":"123","author":"Persky","year":"2018","journal-title":"Appetite."},{"key":"2026031009291654600_ref63","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/j.1530-0277.1995.tb01554.x","article-title":"Development and initial validation of a measure of drinking urges in abstinent alcoholics","volume":"19","author":"Bohn","year":"1995","journal-title":"Alcohol Clin Exp Res"},{"key":"2026031009291654600_ref64","doi-asserted-by":"publisher","first-page":"e00131","DOI":"10.1002\/prp2.131","article-title":"Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses","volume":"3","author":"Keizer","year":"2015","journal-title":"Pharmacol Res Perspect"},{"key":"2026031009291654600_ref65","doi-asserted-by":"publisher","first-page":"e13211","DOI":"10.1111\/adb.13211","article-title":"The glucagon-like peptide-1 system is modulated by acute and chronic alcohol exposure: findings from human laboratory experiments and a post-mortem brain study","volume":"27","author":"Farokhnia","year":"2022","journal-title":"Addict Biol"},{"key":"2026031009291654600_ref66","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/jvim.15416","article-title":"Cardiorenal and endocrine effects of synthetic canine BNP1-32 in dogs with compensated congestive heart failure caused by myxomatous mitral valve disease","volume":"33","author":"Yata","year":"2019","journal-title":"J Vet Intern Med"},{"key":"2026031009291654600_ref67","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1024\/0301-1526\/a001052","article-title":"Prevalence of venous thromboembolism in patients undergoing diagnostic venous ultrasound during the first SARS-CoV-2 pandemic","volume":"52","author":"La Torre","year":"2023","journal-title":"Vasa."},{"key":"2026031009291654600_ref68","doi-asserted-by":"publisher","first-page":"107788","DOI":"10.1016\/j.neuropharm.2019.107788","article-title":"Endocrine effects of the novel ghrelin receptor inverse agonist PF-5190457: results from a placebo-controlled human laboratory alcohol co-administration study in heavy drinkers","volume":"170","author":"Lee","year":"2020","journal-title":"Neuropharmacology"},{"key":"2026031009291654600_ref69","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1210\/edrv.22.1.0419","article-title":"The somatomedin hypothesis: 2001","volume":"22","author":"Le Roith","year":"2001","journal-title":"Endocr Rev"},{"key":"2026031009291654600_ref70","doi-asserted-by":"publisher","first-page":"R212","DOI":"10.1530\/ec-18-0099","article-title":"The growth hormone-insulin-like growth factor-I axis in the diagnosis and treatment of growth disorders","volume":"7","author":"Blum","year":"2018","journal-title":"Endocr Connect"},{"key":"2026031009291654600_ref71","doi-asserted-by":"publisher","DOI":"10.1530\/joe-22-0159","article-title":"Understanding the role of growth hormone in situations of metabolic stress","volume":"256","author":"Tavares","year":"2023","journal-title":"J Endocrinol"},{"key":"2026031009291654600_ref72","doi-asserted-by":"publisher","first-page":"104741","DOI":"10.1016\/j.appet.2020.104741","article-title":"Validation of a virtual reality buffet environment to assess food selection processes among emerging adults","volume":"153","author":"Cheah","year":"2020","journal-title":"Appetite."},{"key":"2026031009291654600_ref73","doi-asserted-by":"publisher","first-page":"107052","DOI":"10.1016\/j.appet.2023.107052","article-title":"Portion size affects food selection in an immersive virtual reality buffet and is related to measured intake in laboratory meals varying in portion size","volume":"191","author":"Long","year":"2023","journal-title":"Appetite."}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ijnp\/advance-article-pdf\/doi\/10.1093\/ijnp\/pyaf081\/66174759\/pyaf081.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/29\/2\/pyaf081\/66174759\/pyaf081.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/29\/2\/pyaf081\/66174759\/pyaf081.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T13:29:27Z","timestamp":1773149367000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijnp\/article\/doi\/10.1093\/ijnp\/pyaf081\/8407681"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,31]]},"references-count":73,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ijnp\/pyaf081","relation":{},"ISSN":["1461-1457","1469-5111"],"issn-type":[{"value":"1461-1457","type":"print"},{"value":"1469-5111","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2025,12,31]]},"article-number":"pyaf081"}}